We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ARAB HEALTH - INFORMA

Download Mobile App




Portable UTI Testing Platform Brings Lab-Quality Molecular Diagnostics to Point-Of-Care Settings

By HospiMedica International staff writers
Posted on 25 Apr 2023
Print article
The UTI assay panel can test for up to six urinary tract infections at the point-of-care (Photo courtesy of Llusern Scientific)
The UTI assay panel can test for up to six urinary tract infections at the point-of-care (Photo courtesy of Llusern Scientific)

Urinary tract infections (UTIs) are among the most prevalent bacterial infections worldwide, with 90% of patients being women and the risk increasing with age. UTIs can be painful, debilitating, and potentially lead to severe long-term complications, such as sepsis. However, suitable point-of-care diagnostic tools are lacking, leading to frequent over- and underdiagnosis. UTI treatments account for 10-20% of community antibiotic prescriptions, but many of these antibiotics are prescribed unnecessarily, contributing to the spread of antibiotic resistance. Now, a new point-of-care UTI test can assist clinicians in making evidence-based decisions for UTI patients.

Llusern Scientific (Wales, UK) is launching its UTI assay panel which can test for up to six UTIs at the point-of-care, revolutionizing the way clinicians test for UTIs. The UTI assay panel will test for Escherichia coli (E-coli), Klebsiella spp, Proteus mirabilis, Staphylococcus saprophyticus, Enterococcus spp, and Pseudomonas aeruginosa. This innovative test delivers results in just 40 minutes, avoiding decisions based on ambiguous clinical symptoms or imprecise urine dipstick tests. Clinical results thus far indicate 93% sensitivity and 99% specificity for the test. Additionally, the portable, user-friendly test requires no sample processing, making it adaptable for use in various patient populations and settings, potentially including community and emergency care.

Llusern’s UTI assay panel will run on Lodestar DX, a portable molecular platform designed for UTI and respiratory disease testing that provides lab-accurate results in 30 minutes. This cost-effective technology enables users to perform Loop-mediated isothermal amplification (LAMP) reactions conveniently. The method allows for the amplification and detection of DNA or RNA in a wide array of bacterial and viral targets. Lodestar DX uses an internal algorithm to determine the positivity or negativity of a LAMP reaction, and this algorithm is compatible with numerous LAMP reactions. The system outputs real-time fluorescent reaction data that can be directly captured on a PC and stored for later offline analysis. Capable of running eight reactions simultaneously, Lodestar DX can be operated flexibly based on user requirements. It can be powered by a mains supply using its power adapter or a 15Vdc source like a standard vehicle lighter plug, enabling its use in remote locations.

 

Gold Member
Disposable Protective Suit For Medical Use
Disposable Protective Suit For Medical Use
Gold Member
12-Channel ECG
CM1200B
New
Transparietal Needle
PIA
New
3T MRI Scanner
MAGNETOM Cima.X

Print article

Channels

Critical Care

view channel
Image: The study used a new electronic diagnostic model as an alternative to kidney biopsies to predict AIN (Photo courtesy of 123RF)

Electronic Diagnostic Model Predicts Acute Interstitial Nephritis in Patients

Acute interstitial nephritis (AIN) is a frequent cause of acute kidney injury (AKI), characterized by inflammation and swelling of certain kidney tissues. It is typically associated with the use of medications... Read more

Surgical Techniques

view channel
Image: A wireless, fully implantable LVAD system could reduce the risk of infections and complications (Photo courtesy of 123RF)

Wireless, Fully Implantable LVAD System to Make Life Easier for Heart Failure Patients

Left Ventricular Assist Devices (LVADs) have traditionally relied on physical drivelines to provide power, creating a connection through the patient's skin. These drivelines increase the risk of infections... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.